Vanguard reports zero beneficial ownership of MaxCyte stock
The Vanguard Group amended a Schedule 13G to report zero beneficial ownership of MaxCyte Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group amended a Schedule 13G to report zero beneficial ownership of MaxCyte Inc. common stock. The amendment explains an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries/divisions to report holdings separately. The filing states 0 shares (0%) beneficially owned and is signed March 27, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does The Vanguard Group report in MXCT?
Why did Vanguard change how it reports MXCT holdings?
Does the filing identify which Vanguard entities now report separately?
When was the Schedule 13G/A amendment signed and filed?
AI-generated analysis. How Rhea-AI works. Not financial advice.